| Literature DB >> 23737875 |
Abstract
The aim of this study was to evaluate the curative effects of eliminating sedimentation inside the prostate via manipulation for the treatment of chronic pelvic pain syndrome (CPPS) using the National Institutes of Health (NIH)-chronic prostatitis symptom index (CPSI) scores. According to the prostatitis classification standard of the NIH, 721 patients with CPPS were divided into groups IIIA and IIIB by prostatic fluid routine examination (EPSRt) and treated using manipulation. The treatment was performed once per 3 days for 3-5 min and 10 treatments were considered to be a period. The EPSRt and NIH-CPSI scores were tested before and at the end of each period following treatment. After 3 treatment periods, the effectiveness and total effectiveness rates of the IIIA group were 72.3 and 15.9%, respectively and those of the IIIB group were 71.8 and 16.3%, respectively. Statistical analysis showed no significant differences between the curative effects in the two groups (P>0.05). The NIH-CPSI scores of the two groups were significantly improved following each treatment period (P<0.01). Eliminating sedimentation using manipulation dispersed the blockage, discharged the turbidity and cleared the gland, leading to the elimination of sedimentation and the relief of sinus hyperemia around the prostate, which significantly improved the clinical symptoms of CPPS and the quality of life of the patients.Entities:
Keywords: NIH-CPSI score; chronic pelvic pain syndrome; eliminating sedimentation; prostate Qi-concentrated single-finger manipulation
Year: 2013 PMID: 23737875 PMCID: PMC3671787 DOI: 10.3892/etm.2013.982
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Comparison of the NIH-CPSI and EPSRt WBC count scores of the two groups (mean ± S).
| Group | Period | Pain | Urine symptoms | Life quality | Total score | WBC count score |
|---|---|---|---|---|---|---|
| IIIA (n=40) | Before | 10.53±3.31 | 7.56±2.29 | 9.35±2.87 | 26.79±8.31 | 2.56±0.87 |
| 1 | 7.38±4.02 | 5.96±2.74 | 7.82±3.21 | 21.79±7.39 | 1.79±0.73 | |
| 2 | 6.10±4.36 | 4.48±2.35 | 6.49±3.31 | 17.98±7.89 | 1.51±0.83 | |
| 3 | 3.83±1.59 | 2.19±1.12 | 3.23±1.37 | 9.13±3.79 | 1.03±1.11 | |
| IIIB (n=281) | Before | 9.93±3.12 | 6.96±2.37 | 8.93±3.25 | 24.99±8.73 | |
| 1 | 7.04±2.13 | 4.93±1.39[ | 6.83±2.23[ | 19.73±5.69[ | ||
| 2 | 5.77±2.27 | 3.39±1.41[ | 5.39±2.14[ | 14.91±6.15[ | ||
| 3 | 2.19±0.93[ | 1.93±1.11 | 2.91±1.31 | 7.53±3.21[ |
P<0.01,
P<0.05, vs. before treatment.
P<0.01,
P<0.05, vs. after treatment in each group. NIH-CPSI, National Institutes of Health-chronic prostatitis symptom index, EPSRt, prostatic fluid routine examination; WBC, white blood cell.
Figure 1Examples of prostatic discharge during treatment. (A) Thick phlegm-like gray jelly-like fluid; (B) rusty blood clot; (C) green jelly-like fluid; (D) gray jelly-like fluid; (E) light yellow jelly-like fluid; (F) creamy white jelly-like fluid; (G) pitch-like blood clot.
Figure 2Examples of prostatic discharge following treatment from different patients. (A and B) Wuliangye alcohol-like prostatic fluids.